

CHIRON CORP  
Form 8-K  
December 09, 2004

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 8, 2004 (December 7, 2004)**

## Chiron Corporation

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**0-12798**  
(Commission  
File Number)

**94-2754624**  
(IRS Employer  
Identification No.)

**4560 Horton Street, Emeryville, CA**  
(Address of principal executive offices)

**94608**  
(Zip Code)

Registrant's telephone number, including area code **(510) 655-8730**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Section 8 Other Events**

**Item 8.01.**

**Other Events**

## Edgar Filing: CHIRON CORP - Form 8-K

On December 7, 2004, Chiron Corporation announced via press release that it had received notification from the UK Medicines and Healthcare products Regulatory Agency (MHRA) that the MHRA proposes to continue the suspension of the company's license to manufacture influenza vaccines in Liverpool for a further period of three months, effective January 4, 2005, which is the date of expiration of the initial three month suspension.

A copy of Chiron's press release is attached hereto as Exhibit 99.1.

**Item 9.01**

**Financial Statements and Exhibits**

(c)

*Exhibits*

99.1

Press release issued on December 7, 2004.

**SIGNATURE**

**SIGNATURE**

Edgar Filing: CHIRON CORP - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CHIRON CORPORATION**  
(Registrant)







Edgar Filing: CHIRON CORP - Form 8-K

Date: December 8, 2004

By:

/s/Ursula B. Bartels  
Ursula B. Bartels

Vice President and  
General Counsel

